Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

 

International Congress of Parkinson’s Disease and Movement Disorders ®

Congress

Parallel Session 2405

Cognitive Impairment in Parkinson's Disease

Monday, October 5, 2026
14:00 - 15:30 | Conference Room North 203, Level 2

In this session, the faculty will discuss the clinical features of cognitive impairment in Parkinson's disease ranging from mild cognitive impairment (MCI) to dementia; the role of biomarkers in understanding pathophysiology and demonstrate therapeutic approaches to a patient with cognitive impairment.

Chairs:

Jennifer Goldman, USA
Louis Tan, Singapore

Presenters:

Clinical Features of MCI and Dementia in Parkinson’s Disease

Pathophysiology and Biomarkers of Cognitive Impairment in Parkinson’s Disease
Carmela Tartaglia, Canada

Therapeutic Approaches to MCI and Dementia in Parkinson's Disease
Cheng-Hsuan Li, Taiwan

CSPC Liaison(s):

Susan Fox, Canada

Learning Objectives

At the conclusion of this session, participants should be better able to:

  1. Describe the clinical symptoms and signs of cognitive impairment in Parkinson's disease
  2. Describe the pathophysiology of Parkinson's disease dementia and interpret radiological, genetic, and proteomic biomarker tests
  3. Design an appropriate treatment plan for a Parkinson's disease patient with cognitive issues

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Health Professional (non-physician)
Industry
Researcher / Basic Science

Education Level

Advanced / Expert
Beginner / Foundational
Intermediate / Experienced